<DOC>
	<DOCNO>NCT01050413</DOCNO>
	<brief_summary>This study aim evaluate serum thymidine kinase 1 ( TK1 ) activity marker solid tumor specifically : preoperative test prediction disease recurrence survival ; follow-up surgical removal original tumor early detection disease recurrence monitoring therapy surrogate marker tumor response .</brief_summary>
	<brief_title>Evaluation Thymidine Kinase Activity Serum Patients With Solid Tumors</brief_title>
	<detailed_description>Thymidine kinase 1 ( TK1 ) metabolic enzyme catalyze ATP-dependent phosphorylation thymidine thymidine monophosphate follow utilization DNA synthesis . It demonstrate activity TK1 serum cancer patient correspond amount divide tumor cell . Several clinical investigation clearly show abnormal TK1 level indicate tumor growth . In breast cancer , serum TK1 show predict increase risk recurrence follow surgery may good marker monitor response therapy . The measurement TK1 useful prognostic monitoring factor patient NSCLC . Unfortunately , previously use assay measure TK1 activity show relatively low analytical sensitivity . Recently , novel high sensitive non-radioactive TK1 assay ( DiviTum ) develop . With assay tumour growth may detect early stage disease small amount residual disease may detect therapy .</detailed_description>
	<criteria>patient colon , breast , prostate lung cancer treatment pregnant woman ; patient generalize CMV HZV infection ; patient severe rheumatoid arthritis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2009</verification_date>
	<keyword>Thymidine Kinase 1 activity</keyword>
	<keyword>diagnosis</keyword>
	<keyword>prognosis</keyword>
	<keyword>follow-up</keyword>
</DOC>